

# Leading Article

## Current Concepts of Estrogen-Regulated Growth Hormone Secretion in Postmenopausal Women

---

JOHANNES D VELDHUIS

General Clinical Research Center, Mayo School of Graduate Medical Education,  
Mayo Clinic, Rochester, MN, USA

Epidemiological investigations correlate organic growth hormone (GH) deficiency (hyposomatotropism) with decreased insulin sensitivity, dyslipidemia, increased cardiovascular mortality, intra-abdominal adiposity, sarcopenia, osteopenia, diminished quality of life, and possibly reduced cognitive function [1,2]. Aging increases the prevalence of these signs and symptoms and is associated with an exponential decline in systemic GH and insulin-like growth factor-I (IGF-I) concentrations, beginning at the transition between late puberty and early adulthood [3–5]. However, maximally stimulated GH secretion, GH elimination kinetics, and the capability of GH to drive hepatic IGF-I production are preserved in the older individual [6–9]. Thus, aging appears to impair the normal regulation of GH secretion, rather than irreversibly reducing the capacity to secrete GH or blocking the actions of GH on the liver.

Visceral adiposity, increasing age, low sex-steroid hormone concentrations, and limited aerobic capacity are major predictors of decreased GH availability [4,10–12]. Substantial weight loss and prolonged aerobic training can double 24 h-integrated GH concentrations in the young adult, but may be less effective in the older individual. However, supplementation with estradiol or an aromatizable androgen (e.g. testosterone) stimulates GH production several-fold in both aging and hypogonadal adults [10,11].


Estrogens are primary agonists, inasmuch as the formation of estradiol from testosterone contributes significantly to the gonadal-steroid drive of GH secretion. Significant advances have been made in elucidating some of the basic mechanisms that mediate estrogenic stimulation of the human somatotrophic axis in older individuals, and these are discussed here.

### Mechanisms of GH control

Clinical studies have combined specific high-sensitivity GH assays, intensive blood-sampling schedules, innovative peptidyl infusions, validated analytical methods, and model-assisted formulations to dissect the mechanisms of GH regulation in health and disease [13]. Such strategies establish that the proximate basis for low GH concentrations in aging individuals is a reduction in the mass of GH secreted per burst (defined as  $\mu\text{g}$  of GH released per unit distribution volume per pulse), with minimal or no change in the basal secretion, pulse frequency, or plasma half-life of GH [4,5,10,11]. The insight that aging selectively reduces GH secretory-burst mass has led to recent investigations focusing on the mechanisms that generate and sustain high-amplitude GH pulses in the healthy young adult [14].

Collectively, data from laboratory and clinical investigations have indicated that coordinated interactions among systemic, hypothalamic, and pituitary peptides and sex steroids jointly govern the amount of GH

**Figure 1.** Schematic illustration of ensemble regulation of GH secretion by the primary peptides GHRH, SS, GHRP/ghrelin, and GH. Stimulatory inputs are marked by continuous arrows and +, and feedback inhibitory pathways by interrupted arrows and - symbols. GH, as well as insulin-like growth factor-I (not shown), enforces negative feedback by evoking SS release and repressing GHRH secretion. SSTR-2 and SSTR-5 denote two subtypes of SS receptors in the pituitary glands. SS-receptor subtypes 1 and 2 mediate intrahypothalamic inhibition of GHRH neurons.




secreted per burst [13,15]. However, the species selectivity of sex-steroid action makes inferences gained in the rat, mouse, pig, and sheep illustrative of, rather than definitive to, the human. For example, estrogens suppress, while non-aromatizable androgens augment, GH pulse height in the rat, but exert opposite effects in the human [12]. Nonetheless, a fundamental inference in all species is that GH-releasing hormone (GHRH, a 41- and 44-amino acid peptide), the GH-releasing peptide (GHRP) ghrelin (28-amino acid peptide), and somatostatin (14-amino acid peptide) constitute a core ensemble of potent GH regulators. Feedback inhibition of GH secretion by systemic IGF-I and GH appears to maintain normal pulsatility by inducing the inhibitor, somatostatin, and repressing the stimulator, GHRH (**Figure 1**). GHRH and somatostatin are produced in discrete hypothalamic nuclei and released into pituitary-portal blood. Ghrelin peptide and gene transcripts are localized predominantly

(>70%) in the gastric fundus, as well as in diencephalic neurons and the pituitary gland [16]. Whether ghrelin is released into hypothalamo-pituitary portal blood under normal physiological conditions is not yet known.

### Estrogenic and androgenic stimulation of GH release

The estradiol-enriched preovulatory phase of the menstrual cycle correlates with a doubling of GH concentration due to a doubling of pulsatile GH secretion [17]. Greater estrogen availability predicts higher mean GH concentrations and larger GH pulses in pre- and postmenopausal women compared with age-matched men [18–20]. In interventional studies, estrogen supplementation in girls with Turner syndrome, postmenopausal women, male-to-female transsexual patients, and men with prostatic cancer increased GH concentrations by 1.8–3.3-fold [2,10,12,21,22]. The route of estrogen delivery is not crucial,

**Figure 2.** Sex-steroid supplementation augments the size (mass) of GH secretory bursts in healthy older men and women [10,11].



with intravenous, intramuscular, oral, intravaginal, intranasal, or higher-dose transdermal estradiol administration stimulating GH secretion [10,12,21–23]. The aromatizable androgen, testosterone, acts analogously [11].

Current analytical methods indicate that the gender distinction in GH concentrations and the stimulatory effects of estradiol and testosterone on GH production arise from the 2-fold augmentation of GH secretory-burst mass (**Figure 2**) [10,11]. This has motivated clinical studies to identify the mechanisms by which estrogen and androgen promote greater GH release within each pulse and, thereby, over 24 h. One goal of such investigations is to create a scientific platform for developing novel strategies to obviate hyposematotropism, employing steroidal and nonsteroidal interventions, in both aging and hypogonadal individuals. Nonsteroidal interventions are of increasing importance in a subset of estrogen-deficient women who may be at increased risk of neoplastic, cerebro- and cardiovascular, thrombophlebitic, and cholestatic disease [24].

### Concept of ensemble-peptide control of GH secretion


Estrogen and testosterone selectively increase, whereas aging and hypogonadism primarily reduce, pulsatile GH production. This

mechanistic insight is important since burst-like GH secretion constitutes the majority (88–94%) of total daily GH output [4,5,10,11,19,20]. Recent advances establish that GH pulse frequency does not vary during the course of development and aging; this leaves GH secretory-burst mass as the principal determinant of pulsatile GH secretion. Because the ensemble of GHRH, somatostatin, GHRP/ghrelin, GH, and IGF-I collectively control GH pulse size, a growing challenge is to visualize how mechanistic interactions govern the generation of GH pulses [13]. This issue has prompted the development of simplified biomathematical models to assist clinical interpretation [15]. Current analytical constructs indicate that consensus linkages among GHRH, somatostatin, and GH/IGF-I, along with the amplifying actions of GHRP/ghrelin, are necessary and sufficient to confer self-renewing, high-amplitude GH secretory bursts. Aging and estrogen appear to modulate each of these key peptidyl pathways.

### Multisite actions of estradiol in the human

Clinical experiments have unveiled distinct hypothalamo-pituitary actions of estradiol that contribute to the amplification of GH secretory-burst mass. In principle, testosterone could drive pulsatile GH

**Figure 3.** Distinct mechanisms by which  $E_2$  promotes pulsatile GH secretion in postmenopausal women. Estrogen decreases the inhibitory potency of SS and increases the stimulatory potency of GHRH, heightens feedback inhibition by rh-insulin-like growth factor-I (A, left to right), facilitates stimulation by GHRP-2 (a ghrelin analogue) in the absence or presence of negative feedback by a pulse of rhGH, and augments post-SS rebound-like GH release that is mediated via endogenous GHRH outflow (B, left to right).



$E_2$ : estradiol; GH: growth hormone; GHRH: growth hormone-releasing hormone; GHRP: growth hormone-releasing peptide; rh: recombinant human; SS: somatostatin.

secretion via analogous mechanisms, although few data are available that directly test this postulate.

In summary, short-term estradiol supplementation in postmenopausal women has the following effects [25–33]:

- Enhances the stimulatory potency of exogenous GHRH pulses.
- Attenuates the inhibitory potency of infused somatostatin.
- Potentiates stimulation by GHRP-2, which is a synthetic analog of ghrelin.
- Mutes negative feedback by a pulse of GH.
- Amplifies post-somatostatin rebound-like release of GH.
- Accentuates inhibition of GH secretion by infused IGF-I.


This set of well-defined mechanisms is illustrated in **Figure 3**. From the collective

evidence, it is likely that estradiol regulates interactions among GHRH, somatostatin, ghrelin, GH, and IGF-I. The aggregate effect is to augment pulsatile (and thereby total) daily GH production.

### Investigation of ensemble mechanisms

A consequence of multipetide control of pituitary-hormone secretion is that modulation of any given regulatory locus will also alter the output of interconnected sites [13]. The latter feature makes clinical inference difficult. For example, the finding that estradiol amplifies GH secretory-burst mass following a submaximal GHRH stimulus could in principle signify that estrogen upregulates somatotrope GHRH receptors, reduces negative feedback by systemic GH, attenuates inhibition by somatostatin, augments GHRH-releasable GH stores,

**Figure 4.** Despite identical  $E_2$  concentrations, postmenopausal women (O) secrete 55-80% less GH in individual secretory bursts than young women (Y) when fasting (A) and in response to each secretagogue pair studied (as indicated in B-D) [37]. Y-axis values are GH secretory-burst mass normalized to experimentally controlled  $E_2$  concentrations ( $\mu\text{g/L}/(\text{pg/mL})$ ).



and/or potentiates the action of ghrelin, which alone stimulates GH secretion and synergizes with GHRH [32,34,35]. Therefore, interpreting precisely how estradiol directs multipetide regulation cannot be easily deduced from any single experiment. Recent studies address this important issue through several new investigative strategies [29,33,36]:

- Simultaneous infusion of two peptides in order to unmask estradiol-dependent control of the heterotypic (non-infused) peptide.
- Feedback induction of hypothalamic somatostatin outflow by exogenous GH, injected prior to peptide infusion, in order to detect estradiol-regulated somatostatin restraint.
- Continuous GHRP stimulation, alone and combined with GHRH, in order to discern estradiol-modulated two-peptide interactions.

Because L-arginine has been shown to reduce somatostatin outflow in experimental animal models, secretagogue infusions occasionally utilize L-arginine combined with GHRH or GHRP-2 (Figure 4) [37]. In the experiment shown in Figure 4, young and older women initially received leuprolide to suppress ovarian estrogen secretion, and then received graded transdermal estradiol supplementation to “clamp” circulating estradiol concentrations equivalently in the two age groups. Fasting and secretagogue-stimulated pulsatile GH secretion rates were significantly reduced in postmenopausal compared with premenopausal women, despite comparable estradiol concentrations. Thus, age, rather than estrogen availability alone, reduces GH secretion in healthy individuals. Model-based analyses predict that impaired two-peptide stimulation in the elderly cohort reflects diminished endogenous drive by GHRH and ghrelin,

and heightened inhibition by hypothalamic somatostatin [15,38].

### Investigative challenges

Elucidating the basis of complex physiological adaptations (e.g. those associated with aging) and pituitary responses to multipolypeptide interventions depends, in part, upon the availability, reliability, and incisiveness of analytical tools. Technical challenges include using serial GH concentrations to estimate regulatory endpoints, such as simultaneous feedback and feedforward within an axis, the timing and mass of underlying GH secretory bursts, constitutive GH release, biexponential elimination kinetics, and random variability in the data associated with sample collection, processing, and assay [15,38]. Recent biomathematical advances address some of these fundamental issues, as illustrated by clinical studies of the somatotrophic, thyrotrophic, corticotrophic, and gonadotrophic axes [15,26,38,39].

### Significance of pulsatile and basal GH outflow to target tissues

In the experimental animal, GH regulates gene expression, in part, by inducing *in situ* IGF-I production and modifying local IGF-binding protein (IGFBP) availability [13,39]. GH promotes synthesis of IGF-I in the liver and kidneys, and systemic secretion of IGF-I by the same organs [40]. In addition, GH may act directly to stimulate lipolysis, pre-chondrocyte proliferation, growth of erythroid precursors, hepatic synthesis of the acid-label subunit and low-density lipoprotein receptor, and hormone and drug metabolism [40–42]. Both local and systemic IGF-I are physiologically important, because marked (>65%) depletion of systemic IGF-I concentrations, achieved in transgenic mice, does not restrict neonatal or pubertal somatic growth, but impairs carbohydrate balance and reduces bone density in the adult animal [40,43].


Sex-steroid hormones govern the actions of available GH, IGF-I, and IGFBPs in diverse target tissues [44]. For example, GH and estrogen modulate the production, turnover, and signaling of central nervous system

IGF-I, which can enhance neurogenesis, cytodifferentiation, and memory in animal models [45]. Thus, an emerging notion is that GH and sex steroids provide conjoined control of tissue-specific IGF-I synthesis, secretion, binding, action, and degradation [12]. An implication of this is that interventions designed to elevate systemic GH concentrations would enhance physiological GH-dependent IGF-I synthesis, and thereby oppose some of the catabolic consequences of aging. At the cellular level, estrogens act via an array of full-length and truncated cognate receptors, which mediate gene repression and induction as well as rapid, membrane-dependent signaling cascades. Among the genes induced is a suppressor of cytokine (and thereby also GH) signaling (SOCS). These mechanisms are discussed elsewhere [46,47].

### Clinical implications

In principle, the adverse consequences of diminished GH availability in aging adults could be overcome by supplementation with recombinant human GH [48,49]. However, there are no definitive safety data that justify long-term administration of GH in healthy older individuals. Injection of high doses of GH in certain clinical settings (such as protracted critical illness) can increase mortality rates, and excessive GH replacement in hypopituitary adults may elicit fluid retention, arthralgias, carpal tunnel syndrome, and (rarely) benign intracranial hypertension [50,51]. Therefore, complementary approaches include unraveling the primary mechanisms that regulate GH secretion and mimicking physiological control by steroid-independent and steroid-dependent means. Two such approaches have been assessed (**Figure 5**). The first approach showed that continuous subcutaneous infusion of GHRP-2 initially quadruples and then maintains 2-fold elevation of GH concentrations in older adults [36]. Another study demonstrated the capability of twice daily injections of GHRH for 3 months to increase total body water, decrease total abdominal fat, and elevate fat-free mass in healthy aging men [52]. In the latter study, stair-climbing and level-walking

**Figure 5.** Continuous subcutaneous infusion of GHRP-2, a ghrelin analogue, elevates GH secretion 4-fold in 24 h and 2-fold after 2 and 4 weeks in older adults (A;  $p < 10^{-4}$ ) [36]. Twice-daily subcutaneous injection of recombinant human GHRH for 3 months in older men increases total body water (B;  $p = 0.021$ ), reduces total abdominal fat (C;  $p < 0.05$ ), and increases fat-free mass (D) [52].



performance also improved significantly after 3 months.

### Conclusion

Tripartite depletion of systemic GH, IGF-I, and sex steroids in healthy postmenopausal women and older men is accompanied by an increased prevalence of clinical, hormonal, biochemical, and structural features of frailty with an attendant increased risk of physical disability and reduced quality of life. Supplementation with estradiol or testosterone augments GH secretion in both genders.

Fundamental mechanisms subserving the stimulatory actions of estrogen and androgen on the hypothalamo-pituitary control of GH secretion are being unraveled. Primary interactions involve the pivotal regulatory peptides GHRH, ghrelin/GHRP, and somatostatin, as well as feedback by GH and IGF-I. Far less is known about the testosterone-mediated mechanisms of stimulation, with the exception that some of its somatotrophic effects are mediated following its aromatization to estradiol. Two recent interventional studies have indicated

that GHRH or GHRP administration for 1–3 months can increase both GH and IGF-I production by approximately 2-fold and modify body composition in older adults [36,52]. Continuing advances in this field should aid in the ultimate development of selective peptidyl, steroidal, nonpeptidyl, and nonsteroidal interventions that facilitate GH secretion in aging and hypogonadal adults.

#### Acknowledgments

We thank Kris Nunez for excellent support in preparing the manuscript, Kandace Bradford for assistance in analyses and graphical work, the General Clinical Research Center (GCRC) for conducting research protocols: M01 RR00585 to the GCRC of the Mayo Clinic and Foundation from the National Center for Research Resources (Rockville, MD, USA), and R01 NIA AG 14799 and AG 19695 from the National Institutes of Health (Bethesda, MD, USA).

**Address for correspondence:** JD Veldhuis, Division of Endocrinology and Metabolism, Department of Internal Medicine, General Clinical Research Center, Mayo Clinic, 200 First Street SW, Rochester Medical Education, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Email: veldhuis.johannes@mayo.edu

## References

- Laughlin GA, Barrett-Connor E, Criqui MH et al. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. *J Clin Endocrinol Metab* 2004;89:114–20.
- Frantz AG, Rabkin MT. Effects of estrogen and sex difference on secretion of human growth hormone. *J Clin Endocrinol Metab* 1965;25:1470–80.
- Finkelstein JW, Roffwarg HP, Boyar RM et al. Age-related change in the twenty-four-hour spontaneous secretion of growth hormone. *J Clin Endocrinol Metab* 1972;35:665–70.
- Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. *J Clin Endocrinol Metab* 1991;73:1081–8.
- Iranmanesh A, South S, Liem AY et al. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men. *Eur J Endocrinol* 1998;139:59–71.
- Arvat E, Ceda GP, Di Vito L et al. Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging. *Pituitary* 1998;1:51–8.
- Greenwood FC, Landon J, Stamp TC. The plasma sugar, free fatty acid, cortisol, and growth hormone response to insulin. I. In control subjects. *J Clin Invest* 1966;45:429–36.
- Lissett CA, Shalet SM. The insulin-like growth factor-I generation test: peripheral responsiveness to growth hormone is not decreased with ageing. *Clin Endocrinol (Oxf)* 2003;58:238–45.
- Arvat E, Ceda G, Ramunni J et al. The IGF-I response to very low rhGH doses is preserved in human ageing. *Clin Endocrinol (Oxf)* 1998;49:757–63.
- Shah N, Evans WS, Veldhuis JD. Actions of estrogen on the pulsatile, nyctohemeral, and entropic modes of growth hormone secretion. *Am J Physiol* 1999;276:R1351–8.
- Gentili A, Mulligan T, Godschalk M et al. Unequal impact of short-term testosterone repletion on the somatotrophic axis of young and older men. *J Clin Endocrinol Metab* 2002;87:825–34.
- Veldhuis JD, Evans WS, Shah N et al., editors. Sex-steroid interactions with growth hormone. New York: Springer-Verlag, 1999.
- Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. *Endocr Rev* 1998;19:717–97.
- Veldhuis JD, Bowers CY. Sex-steroid modulation of growth hormone (GH) secretory control: tripeptidyl ensemble regulation under dual feedback restraint by GH and IGF-I. *Endocrine* 2003;22:25–40.
- Farhy LS, Straume M, Johnson ML et al. Unequal autonegative feedback by GH models the sexual dimorphism in GH secretory dynamics. *Am J Physiol* 2002;282:R753–64.
- Kojima M, Hosoda H, Date Y et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature* 1999;402:656–60.
- Ovesen P, Vahl N, Fisker S et al. Increased pulsatile, but not basal, growth hormone secretion rates and plasma insulin-like growth factor I levels during the preovulatory interval in normal women. *J Clin Endocrinol Metab* 1998;83:1662–7.
- Wennink JM, Delemarre-van de Waal HA, Schoemaker R et al. Growth hormone secretion patterns in relation to LH and estradiol secretion throughout normal female puberty. *Acta Endocrinol (Copenh)* 1991;124:129–35.
- van den Berg G, Veldhuis JD, Frolich M et al. An amplitude-specific divergence in the pulsatile mode of GH secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. *J Clin Endocrinol Metab* 1996;81:2460–6.
- Veldhuis JD, Roemmich JN, Rogol AD. Gender and sexual maturation-dependent contrasts in the neuroregulation of growth hormone secretion in prepubertal and late adolescent males and females – a general clinical research center-based study. *J Clin Endocrinol Metab* 2000;85:2385–94.
- van Kesteren P, Lips P, Deville W et al. The effect of one-year cross-sex hormonal treatment on bone metabolism and serum insulin-like growth factor-1 in transsexuals. *J Clin Endocrinol Metab* 1996;81:2227–32.
- Maurus N, Rogol AD, Veldhuis JD. Increased hGH production rate after low-dose estrogen therapy in prepubertal girls with Turner's syndrome. *Pediatr Res* 1990;28:626–30.
- Lissett CA, Shalet SM. The impact of dose and route of estrogen administration on the somatotrophic axis in normal women. *J Clin Endocrinol Metab* 2003;84:668–72.
- Chlebowski RT, Col N. Menopausal hormone therapy after breast cancer. *Lancet* 2004;363:410–1.
- Shah N, Evans WS, Bowers CY, Veldhuis JD. Oral estradiol administration modulates continuous intravenous growth hormone (GH)-releasing peptide-2-driven GH secretion in postmenopausal women. *J Clin Endocrinol Metab* 2000;85:2649–59.
- Bray MJ, Vick TM, Shah N et al. Short-term estradiol replacement in postmenopausal women selectively mutes somatostatin's dose-dependent inhibition of fasting growth hormone secretion. *J Clin Endocrinol Metab* 2001;86:3143–9.
- Veldhuis JD, Evans WS, Bowers CY. Impact of estradiol supplementation on dual peptidyl drive of growth-hormone secretion in postmenopausal women. *J Clin Endocrinol Metab* 2002;87:859–66.
- Veldhuis JD, Bidlingmaier M, Anderson SM et al. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. *J Clin Endocrinol Metab* 2001;86:3304–10.
- Veldhuis JD, Anderson SM, Patrie JT et al. Estradiol supplementation in postmenopausal women doubles rebound-like release of growth hormone (GH) triggered by sequential infusion and withdrawal of somatostatin: evidence that estrogen facilitates endogenous GH-releasing hormone drive. *J Clin Endocrinol Metab* 2004;89:121–7.

30. Anderson SM, Shah N, Evans WS et al. Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women. *J Clin Endocrinol Metab* 2001;86:551-60.
31. Anderson SM, Wideman L, Patrie JT et al. Estradiol supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion. *J Clin Endocrinol Metab* 2001;86:5904-11.
32. Veldhuis JD, Evans WS, Bowers CY. Estradiol supplementation enhances submaximal feed-forward drive of growth hormone (GH) secretion by recombinant human GH-releasing hormone-1,44-amide in a putatively somatostatin-withdrawn milieu. *J Clin Endocrinol Metab* 2003;88:5484-9.
33. Veldhuis JD, Anderson SM, Kok P et al. Estradiol supplementation modulates growth hormone (GH) secretory-burst waveform and recombinant human insulin-like growth factor-I-enforced suppression of endogenously driven GH release in postmenopausal women. *J Clin Endocrinol Metab* 2004;89:1312-8.
34. Bowers CY, Kleinberg DL, Clemmons DR, editors. Central and Peripheral Mechanisms in Pituitary Disease. Bristol, UK: BioScientifica Ltd., 2002.
35. Hataya Y, Akamizu T, Takaya K et al. A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. *J Clin Endocrinol Metab* 2001;86:4552.
36. Bowers CY, Granda R, Mohan S et al. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. *J Clin Endocrinol Metab* 2004;89:2290-300.
37. Erickson D, Keenan DM, Mielke K et al. Dual secretagogue drive of burst-like growth hormone secretion in postmenopausal compared with premenopausal women studied under an experimental estradiol clamp. *J Clin Endocrinol Metab* 2004;89:4746-54.
38. Veldhuis JD, Straume M, Iranmanesh A et al. Secretory process regularity monitors neuroendocrine feedback and feedforward signaling strength in humans. *Am J Physiol Regul Integr Comp Physiol* 2001;280:R721-9.
39. Keenan DM, Roelfsema F, Biermasz N et al. Physiological control of pituitary hormone secretory-burst mass, frequency and waveform: a statistical formulation and analysis. *Am J Physiol Regul Integr Comp Physiol* 2003;285:R664-73.
40. Le Roith D, Bondy C, Yakar S et al. The somatomedin hypothesis: 2001. *Endocr Rev* 2001;22:53-74.
41. Achermann JC, Brook CG, Robinson IC et al. Peak and trough growth hormone (GH) concentrations influence growth and serum insulin like growth factor-1 (IGF-1) concentrations in short children. *Clin Endocrinol (Oxf)* 1999;50:301-8.
42. Jaffe CA, Turgeon DK, Lown K et al. Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans. *Am J Physiol Endocrinol Metab* 2002;283:E1008-15.
43. Sjögren K, Wallenius K, Liu J-L et al. Liver-derived IGF-I is of importance for normal carbohydrate and lipid metabolism. *Diabetes* 2001;50:1539-45.
44. Dueñas M, Torres-Aleman I, Naftolin F et al. Interaction of insulin-like growth factor-I and estradiol signaling pathways on hypothalamic neuronal differentiation. *Neuroscience* 1996;74:531-9.
45. Loddick SA, Liu XJ, Lu ZX et al. Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke. *Proc Natl Acad Sci U S A* 1998;95:1894-8.
46. Herbison AE. Multimodal influence of estrogen upon gonadotropin-releasing hormone neurons. *Endocr Rev* 1998;19:302-30.
47. Leung KC, Doyle N, Ballesteros M et al. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. *Proc Natl Acad Sci U S A* 2003;100:1016-21.
48. Johannsson G, Grimby G, Sunnerhagen KS et al. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. *J Clin Endocrinol Metab* 1997;82:2877-84.
49. Cuneo RC, Salomon F, Watts GF et al. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. *Metabolism* 1993;42:1519-23.
50. Bengtsson BÅ. Rethink about growth-hormone therapy for critically ill patients. *Lancet* 1999;354:1403-4.
51. Carvalho LR, de Faria ME, Osorio MG et al. Acromegalic features in growth hormone (GH)-deficient patients after long-term GH therapy. *Clin Endocrinol (Oxf)* 2003;59:788-92.
52. Veldhuis JD, Patrie JT, Frick K et al. Sustained GH and IGF-I responses to prolonged high-dose twice-daily GHRH stimulation in middle-aged and older men. *J Clin Endocrinol Metab* 2004;89:6325-30.